Seattle Genetics (SGEN) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Seattle Genetics (SGEN): In Line ADCETRIS Sales Lead to PT Reduction at Piper Jaffray
February 10, 2016 8:57 AM ESTSlowing sales of Seattle Genetics' (NASDAQ: SGEN) ADCETRIS led Piper Jaffray analyst, Edward Tenthoff, to reduce his overall value for the therapy to $1.5 billion from $1.6 billion. This leads to a lower target price for shares of Seattle Genetics of $33 (from $44). The firm maintained a Neutral rating.
ADCETRIS sales grew 27% annually to $226 million in 2015, but we forecast growth will slow to 17% to $265 million (guidance is $255-$275 million) in 2016. ADCETRIS is currently in three Phase III trials that... More
Cantor Fitzgerald Upgrades Seattle Genetics (SGEN) to Buy
February 10, 2016 7:26 AM ESTCantor Fitzgerald upgraded Seattle Genetics (NASDAQ: SGEN) from Hold to Buy with a price target of $38.00.
For an analyst ratings summary and ratings history on Seattle Genetics click here. For more ratings news on Seattle Genetics click here.
Shares of Seattle Genetics closed at $29.04 yesterday.
... More